Literature DB >> 29785825

Pembrolizumab treatment of a patient with xeroderma pigmentosum with disseminated melanoma and multiple nonmelanoma skin cancers.

K H Kraemer1, D Tamura1, S G Khan1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29785825      PMCID： PMC5967649          DOI： 10.1111/bjd.16525

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

1.  Regression of melanoma metastases and multiple non-melanoma skin cancers in xeroderma pigmentosum by the PD1-antibody pembrolizumab.

Authors:  Axel Hauschild; Julia Eichstaedt; Lena Möbus; Katharina Kähler; Michael Weichenthal; Thomas Schwarz; Stephan Weidinger
Journal:  Eur J Cancer       Date:  2017-03-31       Impact factor: 9.162

2.  Efficacy of anti-programmed cell death-1 immunotherapy for skin carcinomas and melanoma metastases in a patient with xeroderma pigmentosum.

Authors:  G Salomon; A Maza; S Boulinguez; C Paul; L Lamant; E Tournier; J Mazereeuw-Hautier; N Meyer
Journal:  Br J Dermatol       Date:  2018-02-26       Impact factor: 9.302

Review 3.  Living with xeroderma pigmentosum: comprehensive photoprotection for highly photosensitive patients.

Authors:  Deborah Tamura; John J DiGiovanna; Sikandar G Khan; Kenneth H Kraemer
Journal:  Photodermatol Photoimmunol Photomed       Date:  2014-02-19       Impact factor: 3.135

4.  Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.

Authors:  Dung T Le; Jennifer N Durham; Kellie N Smith; Hao Wang; Bjarne R Bartlett; Laveet K Aulakh; Steve Lu; Holly Kemberling; Cara Wilt; Brandon S Luber; Fay Wong; Nilofer S Azad; Agnieszka A Rucki; Dan Laheru; Ross Donehower; Atif Zaheer; George A Fisher; Todd S Crocenzi; James J Lee; Tim F Greten; Austin G Duffy; Kristen K Ciombor; Aleksandra D Eyring; Bao H Lam; Andrew Joe; S Peter Kang; Matthias Holdhoff; Ludmila Danilova; Leslie Cope; Christian Meyer; Shibin Zhou; Richard M Goldberg; Deborah K Armstrong; Katherine M Bever; Amanda N Fader; Janis Taube; Franck Housseau; David Spetzler; Nianqing Xiao; Drew M Pardoll; Nickolas Papadopoulos; Kenneth W Kinzler; James R Eshleman; Bert Vogelstein; Robert A Anders; Luis A Diaz
Journal:  Science       Date:  2017-06-08       Impact factor: 47.728

Review 5.  Shining a light on xeroderma pigmentosum.

Authors:  John J DiGiovanna; Kenneth H Kraemer
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551
  5 in total
  5 in total

Review 1.  DNA repair defects and implications for immunotherapy.

Authors:  Katherine M Bever; Dung T Le
Journal:  J Clin Invest       Date:  2018-10-01       Impact factor: 14.808

Review 2.  Xeroderma pigmentosum: an updated review.

Authors:  Alexander Kc Leung; Benjamin Barankin; Joseph M Lam; Kin Fon Leong; Kam Lun Hon
Journal:  Drugs Context       Date:  2022-04-25

Review 3.  Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?

Authors:  Anja Wessely; Theresa Steeb; Ulrike Leiter; Claus Garbe; Carola Berking; Markus Vincent Heppt
Journal:  Int J Mol Sci       Date:  2020-12-06       Impact factor: 5.923

Review 4.  Alterations of DNA damage repair in cancer: from mechanisms to applications.

Authors:  Minlin Jiang; Keyi Jia; Lei Wang; Wei Li; Bin Chen; Yu Liu; Hao Wang; Sha Zhao; Yayi He; Caicun Zhou
Journal:  Ann Transl Med       Date:  2020-12

Review 5.  Impact of DNA damage response defects in cancer cells on response to immunotherapy and radiotherapy.

Authors:  Daniel Czajkowski; Radosław Szmyd; Harriet E Gee
Journal:  J Med Imaging Radiat Oncol       Date:  2022-04-23       Impact factor: 1.667
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.